Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MGAWN1, for treatment of individuals with suspected central nervous system infection due to WNV
Subscribe to our email newsletter
MacroGenics has initiated Paradigm trial, a phase 2 clinical study evaluating MGAWN1. MGAWN1 is a humanized monoclonal antibody, for the treatment of individuals with suspected central nervous system infection due to West Nile Virus.
The Paradigm trial is a randomized, double-blind, multicenter, placebo-controlled study. It is designed to evaluate the safety and efficacy of MGAWN1 in patients greater than or equal to 18 years of age, with signs and symptoms of acute West Nile Neuroinvasive Disease.
Scott Koenig, President and CEO of MacroGenics, said: We are delighted with the initiation of the Paradigm trial as well as the completion of the Phase 1 trial. Currently, there are no approved treatments for individuals with severe West Nile Virus infection. These patients are hospitalized and receive supportive care. Therefore, a therapy that neutralizes the virus and could possibly reduce or prevent complications associated with West Nile Neuroinvasive Disease would represent a significant advancement for these patients.